KRAS mutation is a frequent oncogenic alteration in a broad range of cancer types, including pancreatic cancer (> 80%), colorectal cancer (> 30%), lung cancer (> 30%), cholangiocarcinoma (> 30%), as well as GC (< 10%) (Polom et al., 2019; Timar and Kashofer, 2020). This evidence concerns the gene KRAS and lung carcinoma.